The Quantellect read.As of Nov 19, 2026, 10 active firms cover Structure Therapeutics Inc. American Depositary Shares: 10 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $70.00 to $140.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $106.20 sits 512% above the current $17.36. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.64 next quarter toward $-2.72 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy10100%
Neutral00%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$106.20
+511.8% upside
Average target across 10 active firms as of Nov 19, 2026 vs $17.36 current
Highest Target$140.00
Average Target$106.20
Lowest Target$70.00
Detailed analyst forecasts for GPCR
Showing 1–10 of 10 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 10 of 10 active firms rate GPCR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
GPCR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.64
Range $-0.71 – $-0.55 · 9 analysts · -420% YoY
Next period, 9 analysts expect Structure Therapeutics Inc. American Depositary Shares to earn $-0.64 a share (range $-0.71 – $-0.55), versus $0.20 a year earlier. Full-year consensus is $-2.21, growing to $-2.72 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 9 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $45.5K next year.
Top analysts covering Structure Therapeutics Inc. American Depositary Shares
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GPCR.
#1
Jonathan Wolleben
JMP Securities · Rank #54
Buy
$110.00+533.6% to target
Overall win rate
43%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$75.00+332.0% to target
Overall win rate
45%
+ Follow
#3
Roger Song
Jefferies · Rank #122
Buy
$125.00+620.0% to target
Overall win rate
43%
+ Follow
#4
Terence Flynn
Morgan Stanley · Rank #222
Buy
$126.00+625.8% to target
Overall win rate
36%
+ Follow
#5
EN
Edward Nash
Canaccord Genuity · Rank #270
Buy
$111.00+539.4% to target
Overall win rate
44%
+ Follow
GPCR stock forecast FAQ
What is GPCR's average 12-month price target?+
The 10 active firms with a live target average $106.20 for Structure Therapeutics Inc. American Depositary Shares over the next 12 months, ranging from a $140.00 high to a $70.00 low, as of Nov 19, 2026.
Is GPCR stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for GPCR?+
The Street-high target is $140.00 (Guggenheim), and the Street-low is $70.00 (HC Wainwright & Co.). The average of all 10 active-firm targets is $106.20.
How many active Wall Street firms cover GPCR?+
10 active firms have a recognized rating on Structure Therapeutics Inc. American Depositary Shares as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering GPCR?+
Among analysts who currently cover GPCR, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #54). Their current call is Buy with a $110.00 target.
What is Structure Therapeutics Inc. American Depositary Shares's projected EPS for next quarter?+
The consensus estimate is $-0.64 per share (range $-0.71 – $-0.55) across 9 analysts. Full-year EPS is projected at $-2.21, rising to $-2.72 the following year.
How much revenue is Structure Therapeutics Inc. American Depositary Shares expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $45.5K next year.
Have analysts been upgrading or downgrading GPCR lately?+
As of Nov 19, 2026, 10 of 10 active firms rate GPCR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GPCR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.